# Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

> **NCT03881059** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 203 (actual)

## Conditions studied

- Active Psoriatic Arthritis

## Interventions

- **OTHER:** BMS-986165 Placebo
- **DRUG:** BMS-986165 Dose A
- **DRUG:** BMS-986165 Dose B
- **DRUG:** Ustekinumab
- **OTHER:** Ustekinumab Placebo

## Key facts

- **NCT ID:** NCT03881059
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-01
- **Primary completion:** 2020-04-27
- **Final completion:** 2021-01-27
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2022-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03881059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03881059, "Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03881059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*